Champions Oncology Inc (NASDAQ: CSBR) has reported a loss for its second fiscal quarter (ending October 31) of $-0.15 versus $0.00 for the same period a year ago. For the latest four quarters through October 31, E.P.S. were $-0.71 versus $0.01 for the same period a year ago — a decline of -7200%.
Recent Price Action
On 12/12/23, Champions Oncology Inc (NASDAQ: CSBR) stock suffered a large decline of -6.5%, closing at $4.61. Moreover, this decline was accompanied by exceptionally high trading volume at 319% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -12.2% during the last week.
Current PriceTarget Research Rating
CSBR is expected to be a modest Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
Champions Oncology has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Champions Oncology has a very low Appreciation Score of 2 but a good Power Rating of 78, triggering the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment